AAAAAA
Results:
1-7
|
Results: 7
Authors:
Templeton, A
Dhall, GI
Calder, A
Gomez-Alzugaray, M
Ho, PC
Pretnar-Darovec, A
Sikazwe, C
Jun-Kang, C
Prasad, RNV
Bygdeman, M
Kovacs, L
Kavkasidze, G
Li-Juan, S
Van Look, PFA
von Hertzen, H
Noonan, E
Ali, M
Peregoudov, A
Laperriere, N
von Hertzen, H
Grimes, D
Ali, M
Citation: A. Templeton et al., Lowering the doses of mifepristone and gemeprost for early abortion: a randomised controlled trial, BR J OBST G, 108(7), 2001, pp. 738-742
Authors:
Koh, SCL
Tham, KF
Razvi, K
Oei, PL
Lim, FK
Roy, AC
Prasad, RNV
Citation: Scl. Koh et al., Hemostatic and fibrinolytic status in patients with ovarian cancer and benign ovarian cysts: Could D-dimer and antithrombin III levels be included asprognostic markers for survival outcome?, CL APPL T-H, 7(2), 2001, pp. 141-148
Authors:
Singh, K
Fong, YF
Prasad, RNV
Dong, F
Citation: K. Singh et al., Vaginal misoprostol for pre-abortion cervical priming: is there an optimalevacuation time interval?, BR J OBST G, 106(3), 1999, pp. 266-269
Authors:
Prasad, RNV
Koh, SCL
Viegas, OAC
Ratnam, SS
Citation: Rnv. Prasad et al., Effects on hemostasis after two-year use of low dose combined oral contraceptives with gestodene or levonorgestrel, CL APPL T-H, 5(1), 1999, pp. 60-70
Does an acidic medium enhance the efficacy of vaginal misoprostol for pre-abortion cervical priming?
Authors:
Singh, K
Fong, YF
Prasad, RNV
Dong, F
Citation: K. Singh et al., Does an acidic medium enhance the efficacy of vaginal misoprostol for pre-abortion cervical priming?, HUM REPR, 14(6), 1999, pp. 1635-1637
Authors:
Singh, K
Fong, YF
Prasad, RNV
Dong, F
Citation: K. Singh et al., Evacuation interval after vaginal misoprostol for preabortion cervical priming: A randomized trial, OBSTET GYN, 94(3), 1999, pp. 431-434
Authors:
Fong, YF
Singh, K
Prasad, RNV
Citation: Yf. Fong et al., Severe hyperthermia following use of vaginal misoprostol for pre-operativecervical priming, INT J GYN O, 64(1), 1999, pp. 73-74
Risultati:
1-7
|